These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 4810905)

  • 1. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 2. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N; Lee SH; Kimball AP
    Cancer Res; 1977 Sep; 37(9):3274-9. PubMed ID: 884674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosylcytosine (ara-C).
    Riva CM; Rustum YM; Preisler HD
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):1-8. PubMed ID: 3859925
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum(II) and vincristine in systemic L1210 leukemia.
    Fodstad O; Pihl A
    Cancer Res; 1982 Jun; 42(6):2152-8. PubMed ID: 7200398
    [No Abstract]   [Full Text] [Related]  

  • 6. DCMP therapy in acute leukemia--the experimental and clinical study.
    Ogawa M; Hoshino A
    Nihon Ketsueki Gakkai Zasshi; 1974 Jun; 37(3):344-50. PubMed ID: 4479924
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy of mouse leukemia L1210 by 1-beta-D-arabinofuranosylcytosine and 6-[(4-nitrobenzyl)thio]-9-beta-D-ribofuranosylpurine.
    Cass CE; Muzik H; Paterson AR
    Cancer Res; 1975 May; 35(5):1187-93. PubMed ID: 1120308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of cytosine arabinoside and thiopurines.
    Valeriote F; Vietti T; Edelstein M
    Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210.
    Edelstein M; Valeriote F; Vietti T
    J Natl Cancer Inst; 1977 Apr; 58(4):941-7. PubMed ID: 845997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
    Neil GL; Homan ER
    Cancer Res; 1973 Apr; 33(4):895-901. PubMed ID: 4696483
    [No Abstract]   [Full Text] [Related]  

  • 11. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
    Bhuyan BK; Fraser TJ; Day KJ
    Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations.
    Bhuyan BK; Blowers CL; Neil GL; Bono VH; Day KJ
    Cancer Res; 1977 Sep; 37(9):3204-8. PubMed ID: 560250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N4-Behenoyl-1-beta-D-arabinofuranosylcytosine as a potential new antitumor agent.
    Aoshima M; Tsukagoshi S; Sakurai Y; Oh-ishi JI; Ishida T
    Cancer Res; 1977 Aug; 37(8 Pt 1):2481-6. PubMed ID: 872077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 18. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 19. Histidinol-mediated improvement in the specificity of 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice.
    Warrington RC; Muzyka TG; Fang WD
    Cancer Res; 1984 Jul; 44(7):2929-35. PubMed ID: 6722819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedule-dependent synergism of combinations of hydroxyurea with adriamycin and 1-beta-D-arabinofuranosylcytosine with adriamycin.
    Ritch PS; Occhipinti SJ; Cunningham RE; Shackney SE
    Cancer Res; 1981 Oct; 41(10):3881-4. PubMed ID: 7284997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.